Nektar Therapeutics Dividend
Dividend criteria checks 0/6
Nektar Therapeutics does not have a record of paying a dividend.
Key information
n/a
Dividend yield
-0.01%
Buyback Yield
Total Shareholder Yield | -0.01% |
Future Dividend Yield | 0% |
Dividend Growth | n/a |
Next dividend pay date | n/a |
Ex dividend date | n/a |
Dividend per share | n/a |
Payout ratio | n/a |
Recent dividend updates
No updates
Recent updates
Investor Optimism Abounds Nektar Therapeutics (NASDAQ:NKTR) But Growth Is Lacking
Oct 18Some Nektar Therapeutics (NASDAQ:NKTR) Shareholders Look For Exit As Shares Take 35% Pounding
Jun 19There's No Escaping Nektar Therapeutics' (NASDAQ:NKTR) Muted Revenues Despite A 44% Share Price Rise
Feb 15Nektar Therapeutics' (NASDAQ:NKTR) Business And Shares Still Trailing The Industry
Dec 31Is Nektar Therapeutics (NASDAQ:NKTR) In A Good Position To Invest In Growth?
Nov 06Is Nektar Therapeutics (NASDAQ:NKTR) In A Good Position To Invest In Growth?
Apr 24Here's Why Nektar Therapeutics (NASDAQ:NKTR) Must Use Its Cash Wisely
Jan 24Is Nektar Therapeutics (NASDAQ:NKTR) In A Good Position To Deliver On Growth Plans?
Aug 19Nektar: Time To Abandon Ship
Jul 17Nektar promotes internal executive to CFO role
Jul 01We Think Nektar Therapeutics (NASDAQ:NKTR) Needs To Drive Business Growth Carefully
May 11After A High-Profile Failure In Melanoma, Nektar Therapeutics' Value Shifts To Its Early-Stage Pipeline
Apr 04Analysts Just Made A Major Revision To Their Nektar Therapeutics (NASDAQ:NKTR) Revenue Forecasts
Mar 09Nektar Therapeutics: Beaten Down By 2020
Jan 26Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Insufficient data to determine if NKTR's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if NKTR's dividend payments have been increasing.
Dividend Yield vs Market
Nektar Therapeutics Dividend Yield vs Market |
---|
Segment | Dividend Yield |
---|---|
Company (NKTR) | n/a |
Market Bottom 25% (US) | 1.4% |
Market Top 25% (US) | 4.5% |
Industry Average (Pharmaceuticals) | 2.3% |
Analyst forecast (NKTR) (up to 3 years) | 0% |
Notable Dividend: Unable to evaluate NKTR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate NKTR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate NKTR's payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as NKTR has not reported any payouts.